公开(公告)号：US20150284471A1

公开(公告)日：2015-10-08

申请号：US14363777

申请日：2012-12-07

Applicant: AMGEN INC

Inventor： David Meininger ,  Michael Wittekind ,  John M. Delaney ,  Mingyue Zhou ,  Derek E. Piper

IPC: C07K16/40 ,  A61K45/06 ,  A61K39/395

CPC classification number: C07K16/40 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/30 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92

Abstract: Antigen binding proteins that activate LCAT are provided. Nucleic acids encoding the antigen binding proteins and vectors and cells containing such nucleic acids are also provided. The antigen binding proteins have value in therapeutic methods in which it is useful to modulate HDL particle size, increase plasma levels of HDL-C, and increase reverse cholesterol transport. Accordingly, the antigen binding proteins have utility in the treatment and prevention of atherosclerosis, various cardiovascular diseases and cholesterol-related disorders, inflammatory conditions, thrombosis-related conditions, metabolic syndrome, diabetes and insulin-resistance. The LCAT antigen binding proteins are also useful in treating the consequences, symptoms, and/or pathology associated with either genetic or acquired LCAT deficiency, including chronic kidney disease (CKD).

Abstract translation: 提供激活LCAT的抗原结合蛋白。 还提供了编码抗原结合蛋白的核酸和含有此类核酸的载体和细胞。 抗原结合蛋白在治疗方法中具有价值，其中它可用于调节HDL颗粒大小，增加HDL-C的血浆水平，并增加反向胆固醇转运。 因此，抗原结合蛋白可用于治疗和预防动脉粥样硬化，各种心血管疾病和胆固醇相关疾病，炎性病症，血栓形成相关病症，代谢综合征，糖尿病和胰岛素抵抗。 LCAT抗原结合蛋白也可用于治疗与遗传或获得性LCAT缺乏症（包括慢性肾脏病（CKD））相关的后果，症状和/或病理学。